CHINA Wang Yi hails Peru's decision to test Chinese vaccine in phase 3 trial


Wang Yi hails Peru's decision to test Chinese vaccine in phase 3 trial


08:49, November 06, 2020

A staff member displays a sample of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group Co., Ltd. (Sinopharm) in Beijing, April 10, 2020. (Photo: Xinhua)

China supports Peru's efforts to arrange a phase 3 clinical trial for a potential COVID-19 vaccine developed by China National Pharmaceutical Group (Sinopharm), Chinese State Councilor and Foreign Minister Wang Yi said on Thursday, adding that the move shows a high degree of trust between the two countries.

In a phone conversation with Peruvian Foreign Minister Mario Lopez, Wang said China understands Peru's need to purchase COVID-19 vaccines. He reiterated China's commitment that its vaccines, once developed and put into use, will be made a global public good and provided to developing countries on a priority basis. 

Health authorities of Peru approved the phase 3 clinical trial for the Sinopharm vaccine in August. 

Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy and safety of potential vaccines for final regulatory approvals.

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue